Sionna Therapeutics to Present at the North American Cystic Fibrosis Conference
BOSTON, Oct. 4, 2022 /PRNewswire/ -- Sionna Therapeutics, a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today announced that it will present preclinical data on novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations at the Cystic Fibrosis Foundation's North American Cystic Fibrosis Conference (NACFC) 2022 to be held November 3-5 at the Pennsylvania Convention Center in Philadelphia. These combinations include Sionna's first-in-class molecules that target the first nucleotide-binding domain (NBD1) of CFTR, with the potential to enable full restoration of CFTR function in CF patients with the ΔF508 mutation.